Progenitor, Inc.

In December 1998, Progenitor, Inc. went out of business. The company announced that it would cease its operations immediately, pursuant to which Progenitor would implement an orderly sale of its assets. Progenitor, Inc. was engaged in the discovery and functional characterization of genes to identify therapeutic leads and targets for the development of new pharmaceuticals, as of June 30, 1998. It focused on the identification of genes in blood and immune cell development, blood vessel development, cancer, and asthma.